Table 1.

Baseline Characteristics of CORRONA Cohort Newly Initiating a DMARD with at least 1 follow-up visit (n = 2,104 unique persons), by Drug Exposure

Drug Exposure	MTX + LEF	MTX	LEF	No MTX or LEF
Number of treatment periods*	103	1342	157	502
Anti-TNF Use, %	27.2	54.9	42.0	75.1
PsA diagnosis**, %	1.9	6.2	3.8	12.0
Age (yrs)	58.8 +- 12.8	59.1 +- 13.3	59.4 +- 14.4	56.9 +- 14.9
Duration of Disease (yrs)	12.9 +- 11.4	10.8 +- 9.8	11.0 +- 8.8	11.9
Female, %	80.6	74.0	78.3	70.9
White, %	83.5	84.7	85.9	82.4
Private Insurance, %	76.6	76.6	72.4	78.0
Medicare Insurance, %	42.9	37.5	45.7	37.1
Medicaid Insurance, %	13.0	5.8	5.5	6.9
Current smoker, %	18.6	15.3	23.5	15.5
Body mass index	28.7 +- 7.0	29.3 +- 7.1	27.9 +- 6.2	29.2 +- 7.5
Diabetes, %	6.8	6.3	10.2	6.8
Liver Disorder, %	6.8	3.7	7.0	9.2
Number of prior other non-biologic DMARDs	0.6 ± 0.8	0.8 ± 1.1	0.7 ± 1.0	0.8 ± 1.0
Use of Folic acid, %	76.6	76.6	28.4	23.6
Use of a Cholesterol Medication, %	18.2	16.3	20.5	15.1
Use of an NSAID, %	46.6	45.1	44.6	48.0
Drinking alcohol, %
None or occasional	77.8	78.0	69.9	68.1
1–3 drinks per week	20.2	18.2	22.6	25.3
1–2 per day	2.0	3.9	7.5	6.6
≥ 3 per day	0.0	0.4	0.7	0.8
Daily prednisone dose	54.5	65.2	56.4	66.7
None	17.8	12.8	11.5	9.8
< 5 mg	21.8	15.2	19.2	15.0
5–10 mg	5.9	6.8	12.8	8.4
≥ 10 mg
Health Services Utilization during observation period after drug initiation
Number of follow-up visits, mean	2.9 ± 2.5	3.7 ± 2.6	3.4 ± 2.9	3.2 ± 2.5
Number of follow-up visits with liver enzyme tests available	2.3 ± 1.1	2.1 ± 1.0	2.2 ± 1.0	1.8 ± 1.0

Data are shown as proportions or mean ± standard deviation

^*a treatment period indicates that a person was newly exposed to this drug or drug combination

^**reflects the proportion of treatment periods contributed by patients with psoriatic arthritis; the remainder of the treatment periods were contributed by rheumatoid arthritis patients